Caroline Rousseau

Dr. Caroline Rousseau

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
TCThomas Carlier
Thomas Carlier
TEThomas Eugène
Thomas Eugène
CBCaroline Bodet-Milin
Caroline Bodet-Milin
EGEtienne Garin
Etienne Garin
CACatherine Ansquer
Catherine Ansquer
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
Despite the early theoretical prediction of the 0+-0+ transition of 90Zr, 90Y-PET underwent only recently a growing interest for the development of imaging radioembolization of liver tumors. The aim of this work was to determine the minimum detectable activity (MDA) of 90Y by PET imaging and the impact of time-of-flight (TOF) reconstruction on detectability and quantitative accuracy according to the lesion size. The study was conducted using a Siemens Biograph® mCT with a 22 cm large axial field of view. An IEC torso-shaped phantom containing five coplanar spheres was uniformly filled to achieve sphere-to-background ratios of 40:1. The phantom was imaged nine times in 14 days over 30 min. Sinograms were reconstructed with and without TOF information. A contrast-to-noise ratio (CNR) index was calculated using the Rose criterion, taking partial volume effects into account. The impact of reconstruction parameters on quantification accuracy, detectability, and spatial localization of the signal was investigated. Finally, six patients with hepatocellular carcinoma and four patients included in different 90Y-based radioimmunotherapy protocols were enrolled for the evaluation of the imaging parameters in a clinical situation. The highest CNR was achieved with one iteration for both TOF and non-TOF reconstructions. The MDA, however, was found to be lower with TOF than with non-TOF reconstruction. There was no gain by adding TOF information in terms of CNR for concentrations higher than 2 to 3 MBq mL−1, except for infra-centimetric lesions. Recovered activity was highly underestimated when a single iteration or non-TOF reconstruction was used (10% to 150% less depending on the lesion size). The MDA was estimated at 1 MBq mL−1 for a TOF reconstruction and infra-centimetric lesions. Images from patients treated with microspheres were clinically relevant, unlike those of patients who received systemic injections of 90Y. Only one iteration and TOF were necessary to achieve an MDA around 1 MBq mL−1 and the most accurate localization of lesions. For precise quantification, at least three iterations gave the best performance, using TOF reconstruction and keeping an MDA of roughly 1 MBq mL−1. One and three iterations were mandatory to prevent false positive results for quantitative analysis of clinical data. http://IDRCB2011-A00043-38P101103

Verified
Journal Article
Open access
PDF file
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
CRCaroline Rousseau
Caroline Rousseau
CBCaroline Bodet-Milin
Caroline Bodet-Milin
CMCédric Mathieu
Cédric Mathieu
FGFrançois Guérard
François Guérard
JBJacques Barbet
Jacques Barbet
This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.

3 March 2012 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
CRCaroline Rousseau
Caroline Rousseau
LFLudovic Ferrer
Ludovic Ferrer
Stéphane SupiotStéphane Supiot
Stéphane Supiot
MBManuel Bardiès
Manuel Bardiès
FDFrançois Davodeau
François Davodeau
MCMichel Cherel
Michel Cherel

1 March 2019 in Bulletin du Cancer
Verified
Journal Article
Closed access
PSPierre-Yves Salaün
Pierre-Yves Salaün
RARonan Abgral
Ronan Abgral
Olivier MalardOlivier Malard
Olivier Malard
SQSolène Querellou-Lefranc
Solène Querellou-Lefranc
GQGilles Quere
Gilles Quere
FCFlorent Cachin
Florent Cachin

1 March 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
LALoic Ah-Thiane
Loic Ah-Thiane
PHPierre Etienne HEUDEL
Pierre Etienne HEUDEL
MCMario Campone
Mario Campone
MRMarie Robert
Marie Robert
VBVictoire Brillaud-Meflah
Victoire Brillaud-Meflah
JFJean-Sebastien FRENEL
Jean-Sebastien FRENEL
PURPOSE: To determine the accuracy of large language models (LLMs) in generating appropriate treatment options for patients with early breast cancer on the basis of their medical records. MATERIALS AND METHODS: Retrospective study using anonymized medical records of patients with BC presented during multidisciplinary team meetings (MDTs) between January and April 2024. Three generalist artificial intelligence models (Claude3-Opus, GPT4-Turbo, and LLaMa3-70B) were used to generate treatment suggestions, which were compared with experts' decisions. The primary outcome was the rate of appropriate suggestions from the LLMs, compared with the reference experts' decisions. The secondary outcome was the LLMs' performances (F1 score and specificity) in generating appropriate suggestions for each treatment category. RESULTS: The rates of appropriate suggestions were 86.6% (97/112), 85.7% (96/112), and 75.0% (84/112) for Claude3-Opus, GPT4-Turbo, and LLaMa3-70B, respectively. No significant difference was found between Claude3-Opus and GPT4-Turbo ( P = .85), but both tended to perform better than LLaMa3-70B ( P = .027 and P = .043, respectively). LLMs showed high accuracy for adjuvant endocrine therapy and targeted therapy indications. However, they tended to overestimate the need for adjuvant radiotherapy and had variable performances in suggesting adjuvant chemotherapy and genomic tests. CONCLUSION: LLMs, particularly Claude3-Opus and GPT4-Turbo, demonstrated promising accuracy in suggesting appropriate adjuvant treatments for patients with early BC on the basis of their medical records. Although LLMs showed limitations in validating surgery and indicating genomic tests, their performance in other treatment modalities highlights their potential to automate and augment decision making during MDTs. Further studies with fine-tuned LLMs and a prospective design are needed to demonstrate their utility in clinical practice.

14 October 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
ALAlexandre LUGAT
Alexandre LUGAT
CBClément Bailly
Clément Bailly
MCMichel Chérel
Michel Chérel
CRCaroline Rousseau
Caroline Rousseau
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
MBMickaël BOURGEOIS
Mickaël BOURGEOIS
Radioimmunoconjugates have been used for over 30 years in nuclear medicine applications. In the last few years, advances in cancer biology knowledge have led to the identification of new molecular targets specific to certain patient subgroups. The use of these targets in targeted therapies approaches has allowed the developments of specifically tailored therapeutics for patients. As consequence of the PET-imaging progresses, nuclear medicine has developed powerful imaging tools, based on monoclonal antibodies, to in vivo characterization of these tumor biomarkers. This imaging modality known as immuno-positron emission tomography (immuno-PET) is currently in fastest-growing and its medical value lies in its ability to give a non-invasive method to assess the in vivo target expression and distribution and provide key-information on the tumor targeting. Currently, immuno-PET presents promising probes for different nuclear medicine topics as staging/stratification tool, theranostic approaches or predictive/prognostic biomarkers. To develop a radiopharmaceutical drug that can be used in immuno-PET approach, it is necessary to find the best compromise between the isotope choice and the immunologic structure (full monoclonal antibody or derivatives). Through some clinical applications, this paper review aims to discuss the most important aspects of the isotope choice and the usable proteic structure that can be used to meet the clinical needs.